Evidence-based pharmacological treatment of generalized anxiety disorder

International Journal of Neuropsychopharmacology

Volumn 14, Issue 5, 2011, Pages 697-710

  Baldwin, David S ^a,d   Waldman, Sarah ^b   Allgulander, Christer ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHERN HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Academic Hospital   (United Kingdom)

Author keywords

Drug treatment; evidence based guidelines; generalized anxiety disorder

Indexed keywords

AGOMELATINE; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; CLONAZEPAM; DIAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; HYDROXYZINE; IMIPRAMINE; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; PREGABALIN; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE; ZONISAMIDE;

BREAST FEEDING; CLINICAL FEATURE; COGNITIVE THERAPY; COMORBIDITY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR DEPRESSION; MEMORY DISORDER; METABOLIC SYNDROME X; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; OPTIMAL DRUG DOSE; PATIENT COUNSELING; PREGNANCY; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; TERATOGENICITY; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DOPAMINE UPTAKE INHIBITORS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; STRESS DISORDERS, TRAUMATIC, ACUTE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79956057325     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710001434     Document Type: Review

References (129)

1. Allgulander C (2008). Antipsychotics in anxiety disorders. European Neuropsychopharmacology 18 (Suppl. 4), S199-S200.
2. Allgulander C (2009). Generalized anxiety disorder (GAD): from now to DSM-V. Psychiatric Clinics of North America 32, 611-628.
3. Allgulander C (2010). Novel approaches to treatment of generalised anxiety disorder. Current Opinion in Psychiatry 23, 37-42.
4. Allgulander C, Dahl AA, Austin C, Morris PL, et al. (2004). Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. American Journal of Psychiatry 161, 1642-1649. (Pubitemid 39201462)
5. Allgulander C, Florea I, Huusom AK (2006). Prevention of relapse in generalized anxiety disorder by escitalopram treatment. International Journal of Neuropsychopharmacology 9, 495-505. (Pubitemid 44607202)
6. Allgulander C, Hackett D, Salinas E (2001). Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. British Journal of Psychiatry 179, 15-22.
7. Allgulander C, Nutt DJ (in press). Benzodiazepines. In: Stolerman I, Lader M (Eds). Encyclopedia of Psychopharmacology. Springer Verlag.
8. Angst J, Gamma A, Baldwin DS, et al. (2009). The generalized anxiety spectrum: prevalence, onset, course and outcome. European Archives of Pyschiatry and Clinical Neuroscience 259, 37-45.
9. Baldwin DS (2004). Sexual dysfunction associated with antidepressant drugs. Expert Opinion on Drug Safety 3, 457-470. (Pubitemid 39242720)
10. Baldwin DS, Ajel K (2007). The role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatric Disease and Treatment 3, 185-191. (Pubitemid 46864058)
11. Baldwin DS, Anderson IM, Nutt DJ, et al. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British association for Psychopharmacology. Journal of Psychopharmacology 19, 567-596. (Pubitemid 41578819)
12. Baldwin DS, Bridgman K, Buis C (2006b). Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. Journal of Psychopharmacology 20, 91-96.
13. Baldwin DS, Huusom AKT, Maehlum E (2006a). Escitalopram and paroxetine in the treatment of generalised anxiety disorder. Randomised, double-blind, placebo-controlled study. British Journal of Psychiatry 189, 264-272. (Pubitemid 44343473)
14. Baldwin DS, Montgomery SA, Nil R, Lader M (2007b). Discontinuation symptoms in depression and anxiety disorders. International Journal of Neuropsychopharmacology 10, 73-84. (Pubitemid 46122754)
15. Baldwin DS, Moreno R, Briley M (2008). Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Human Psychopharmacology 23, 527-532.
16. Baldwin DS, Polkinghorn C (2005). Evidence-based pharmacotherapy of generalized anxiety disorder. International Journal of Neuropsychopharmacology 8, 293-302. (Pubitemid 40769270)
17. Baldwin DS, Reines EH, Guiton C, Weiller E (2007a). Escitalopram therapy for major depression and anxiety disorders. Annals of Pharmacotherapy 41, 1583-1592. (Pubitemid 47485624)
18. Baldwin DS, Stein DJ, Dolberg OT, Bandelow B (2009). How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Human Psychopharmacology 24, 269-275.
19. Baldwin DS, Waldman S (2009). Antipsychotic drugs in the treatment of generalized anxiety disorder. International Journal of Psychiatry in Clinical Practice 13 (Suppl. 1), S11.
20. Ballenger JC (1999). Clinical guidelines for establishing remission in patients with depression and anxiety. Journal of Clinical Psychiatry 60 (Suppl. 22), 29-34. (Pubitemid 30107953)
21. Bandelow B, Baldwin DS, Dolberg OT, Anderson HF, et al. (2006). What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? Journal of Clinical Psychiatry 67, 1428-1434. (Pubitemid 44583391)
22. Bandelow B, Chouinard G, Bobes J, Ahokas A, et al. (2010). Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. International Journal of Neuropsychopharmacology 13, 305-320.
23. Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, et al. (2007). Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World Journal of Biological Psychiatry 8, 175-187. (Pubitemid 47163383)
24. Bandelow B, Zohar J, Hollander E, Kasper S, et al. (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World Journal of Biological Psychiatry 9, 248-312.
25. Bech P (2007). Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 40, 163-168. (Pubitemid 47434876)
26. Beekman AT, Bremmer MA, Deeg DJ, van Balkom AJ, et al. (1998). Anxiety disorders in later life: a report from the longitudinal Aging Study Amsterdam. International Journal of Geriatric Psychiatry 13, 717-726. (Pubitemid 28491262)
27. Beesdo K, Knappe S, Pine DS (2009). Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatric Clinics of North America 32, 483-524.
28. Bodkin JA, Allgulander C, Llorca PM, Spann M, et al. (2009). Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder. ACNP 4th Annual Meeting Final Programme, 6-10 December 2009, Hollywood, Florida (www.acnp.org/ asset.axd?id=a55d7404-334e-43df-a40c- 9cda68719743).
29. Brawman-Mintzer O, Knapp RG, Nietert PJ (2005). Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. Journal of Clinical Psychiatry 66, 1321-1325. (Pubitemid 41546513)
30. Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, et al. (2006). Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 67, 874-881. (Pubitemid 44049085)
31. Bruce SE, Yonkers KA, Otto MW, Eisen JL, et al. (2005). Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. American Journal of Psychiatry 162, 1179-1187. (Pubitemid 40770702)
32. Canadian Psychiatric Association (2006). Clinical practice guidelines. Management of anxiety disorders. Canadian Journal of Psychiatry 51, 9S-91S.
33. Carney CE, Segal ZV, Edinger JD, Krystal AD (2007). A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. Journal of Clinical Psychiatry 68, 254-260. (Pubitemid 46362647)
34. Cervena K, Matousek M, Prasko J, Brunovsky M, et al. (2005). Sleep disturbances in patients treated for panic disorder. Sleep Medicine 6, 149-153. (Pubitemid 40247177)
35. Chessick CA, Allen MH, Thase M, Batista Miralha da Cunha AB, et al. (2006). Azapirones for generalized anxiety disorder. Cochrane Database of Systematic Reviews 3, CD006115.
36. Davidson JR, Bose A, Korotzer A, Zheng H (2004). Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depression and Anxiety 19, 234-240. (Pubitemid 39014143)
37. Davidson JR, DuPont RL, Hedges D, Haskins JT (1999). Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Journal of Clinical Psychiatry 60, 528-535. (Pubitemid 29413473)
38. Davidson JRT, Wittchen H-U, Llorca P-M, Erickson J, et al. (2008). Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. European Neuropsychopharmacology 18, 673-681.
39. Downing RW, Rickels K (1985). Early treatment response in anxious outpatients treated with diazepam. Acta Psychiatrica Scandinanvica 72, 522-528. (Pubitemid 16175949)
40. El-Khayat R, Baldwin DS (1998). Antipsychotic drugs for non-psychotic patients: assessment of the benefit/risk ratio in generalized anxiety disorder. Journal of Psychopharmacology 12, 323-329. (Pubitemid 28561435)
41. Eriksson H, Mezhebovsky I, Magi K, She F, et al. (2008). Double-blind, randomised study of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with generalized anxiety disorder. International Journal of Psychiatry in Clinical Practice 12, 322-333.
42. European Medicines Agency (2005). Committee for Medicinal products for Human Use (CHMP). Guideline on the clinical investigation of medicinal products indicated for generalised anxiety disorder. CPMP/EWP/4284/02, London, January 2005.
43. Fava M (2000). Weight gain and antidepressants. Journal of Clinical Psychiatry 61 (Suppl. 11), 37-41. (Pubitemid 30616693)
44. Feltner D, Wittchen HU, Kavoussi R, Brock J, et al. (2008). Long-term efficacy of pregabalin in generalized anxiety disorder. International Clinical Psychopharmacology 23, 18-28. (Pubitemid 350294866)
45. Feltner DE, Crockatt JG, Dobovsky SJ, Cohn CK, et al. (2003). A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 23, 240-249. (Pubitemid 36807791)
46. Food and Drug Administration (FDA) (2006). New controversial clinical trial design gives better long-term data. FDA Week, 10 May 2006.
47. Gao K, Sheehan DV, Calabrese JR (2009). Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Reviews in Neurotherapeutics 9, 1147-1158.
48. Garner M, Möhler H, Stein DJ, Mueggler T, et al. (2009). Research in anxiety disorders: from the bench to the bedside. European Neuropsychopharmacology 19, 381-390.
49. Geddes JR, Carney SM, Davies C, Furukawa T, et al. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361, 653-661. (Pubitemid 36246547)
50. Gelenberg AJ, Lydiard B, Rudolph RL, Aguiar L, et al. (2000). Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder. Journal of the American Medical Association 283, 3082-3088. (Pubitemid 30399718)
51. Goodman WK, Bose A, Wang Q (2005). Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. Journal of Affective Disorders 87, 161-167. (Pubitemid 41039938)
52. Gould RA, Otto MW, Pollack MH, Yap L (1997). Cognitive behavioural and pharmacological treatment of generalised anxiety disorder: a preliminary meta-analysis. Behaviour Therapy 28, 285-305. (Pubitemid 27422460)
53. Guy W (1976). The clinical global impression severity and impression scales. In: ECDEU Assessment Manual for Psychopathology (pp. 218-222). Rockville, MD: US Department of Health, Education and Welfare.
54. Hackett D, White C, Salinas E (2000). Relapse prevention in patients with generalised anxiety disorder (GAD) by treatment with venlafaxine ER. Poster presented at 1st International Forum on Mood and Anxiety Disorders, Monte Carlo, November 2000 (www.aimgroup.it/2000/ ifmad/POSTER20.htm). Accessed 6 July 2010.
55. Hallberg P, Sjöblom V (2005). The use of selective serotonin inhibitors during pregnancy and breast-feeding: a review and clinical aspects. Journal of Clinical Psychopharmacology 25, 59-73. (Pubitemid 40129383)
56. Hamilton M (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology 32, 50-55.
57. Hartford J, Kornstein S, Liebowitz M, Pigott T, et al. (2007). Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. International Clinical Psychopharmacology 22, 167-174. (Pubitemid 46559873)
58. Hewett K, Adams A, Bryson H, et al. (2001). Generalized anxiety disorder: efficacy of paroxetine. Paper presented at the 7th World Congress of Biological Psychiatry, Berlin, Germany.
59. Hidalgo RB, Tupler LA, Davidson JRT (2007). An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. Journal of Psychopharmacology 21, 864-872. (Pubitemid 350029180)
60. Hoyer J, Gloster AT (2009). Psychotherapy for generalized anxiety disorder: Don't worry, it works! Psychiatric Clinics of North America 32, 629-640.
61. Hunot V, Churchill R, Silva de Lima M, et al. (2007). Psychological therapies for generalized anxiety disorder [Review]. Cochrane Database of Systematic Reviews. Issue No. 24. Art. No. CD001848.
62. Judd LL, Kessler RC, Paulus MP, Zeller PV, et al. (1998). Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Survey (NCS). Acta Psychiatrica Scandinavica 98 (Suppl. 393), 6-11. (Pubitemid 28428186)
63. Kasper S, Herman B, Nivoli G, Van Ameringen M, et al. (2009). Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. International Clinical Psychopharmacology. Published online: January 2009. doi:10.1097/YIC. 0b013e32831d7980.
64. Katzman M, Brawman-Mintzer O, Reyes E, Olausson B, et al. (2008a). Extended release quetiapine fumarate (quetiapine XR) monotherapy in long-term treatment of generalized anxiety disorder (GAD): efficacy and tolerability results from a randomized, placebo-controlled trial. Biological Psychiatry 63 (Suppl.), 141S.
65. Katzman MA, Vermani M, Jacobs L, Marcus M, et al. (2008b). Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. Journal of Anxiety Disorders 22, 1480-1486.
66. Kessler RC, DuPont RL, Berglund P (1999). Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. American Journal of Psychiatry 156, 1915-1923.
67. Kinrys G, Vasconcelos E Sa D, Nery F (2007). Adjunctive zonisamide for treatment refractory anxiety. International Journal of Clinical Practice 61, 1050-1053. (Pubitemid 46744065)
68. Koponen H, Allgulander C, Erickson J, Dunayevich E, et al. (2007). Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Primary Care Companion Journal of Clinical Psychiatry 9, 100-107. (Pubitemid 46607463)
69. Laakmann G, Schüle C, Lorkowski G, Baghai T, et al. (1998). Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology 136, 357-366. (Pubitemid 28189665)
70. Lenox-Smith AJ, Reynolds A (2003). A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. British Journal of General Practice 53, 772-777. (Pubitemid 37254121)
71. Lenze EJ, Rollman BL, Shear MK, Dew MA, et al. (2009). Escitalopram for older adults with generalised anxiety disorder: a randomized controlled trial. Journal of the American Medical Association 301, 295-303.
72. Leonardo ED, Hen R (2008). Anxiety as a developmental disorder. Neuropsychopharmacology 33, 134-140. (Pubitemid 350191317)
73. Levinson-Castiel R, Merlob P, Linder N, Sirota L, et al. (2006). Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Archives of Paediatric and Adolescent Medicine 160, 173-176. (Pubitemid 43213863)
74. Maina G, Albert U, Salvi V, Bogetto F (2004). Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. Journal of Clinical Psychiatry, 63, 391-395.
75. Martens EJ, de Jonge P, Na B, Cohen BE, et al. (2010). Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease. Archives of General Psychiatry 67, 750-758.
76. Martin JLR, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, et al. (2007). Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. Journal of Psychopharmacology 21, 774-782. (Pubitemid 47437920)
77. Mathew SJ, Price RB, Mao X, Smith EL, et al. (2008). Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biological Psychiatry 63, 891-898. (Pubitemid 351458451)
78. Meredith C, Cutler A, Neijber A, She F, et al. (2008). Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the treatment of GAD. European Neuropsychopharmacology 18 (Suppl. 4), S499-S450.
79. Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, et al. (1999). Changes in weight during a 1-year trial of fluoxetine. American Journal of Psychiatry 156, 1170-1176. (Pubitemid 29374875)
80. Misri S, Reebye P, Kendrick K, Carter D, et al. (2006). Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. American Journal of Psychiatry 163, 1026-1032. (Pubitemid 44464489)
81. Mitte K, Noack P, Steil R, Hautzinger M (2005). A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. Journal of Clinical Psychopharmacology 25, 141-150. (Pubitemid 40395092)
82. Montgomery S, Chatamra K, Pauer L, Whalen E, et al. (2008). Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. British Journal of Psychiatry 193, 389-394.
83. Montgomery SA, McIntyre RS, Szamosi J, Eriksson HA, et al. (2009). Extended release quetiapine fumarate monotherapy in patients with MDD: a pooled analysis of sustained response data from studies D1448C00001 and D1448C00002. International Journal of Psychiatry in Clinical Practice 13 (Suppl. 1), S39.
84. Montgomery SA, Sheehan DV, Meoni P, Haudiquet V, et al. (2002). Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. Journal of Psychiatric Research 36, 209-217. (Pubitemid 34626371)
85. Montgomery SA, Tobias K, Zornberg GL, Kasper S, et al. (2006). Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. Journal of Clinical Psychiatry 67, 771-782. (Pubitemid 43946184)
86. Morris PLP, Dahl AA, Kutcher S, Sogaard JA, et al. (2003). Efficacy of sertraline for the acute treatment of generalized anxiety disorder. European Neuropsychopharmacology 13, S375.
87. Munk-Jorgensen P, Allgulander C, Dahl AA, Foldager L, et al. (2006). Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden. Psychiatric Services 57, 1738-1744. (Pubitemid 46051328)
88. Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ (1986). Review of the side-efect profile of buspirone. American Journal of Medicine 31, 17-21.
89. Nitschke JB, Sarinopoulos I, Oathes DJ, et al. (2009). Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. American Journal of Psychiatry 166, 302-310.
90. Olatunji BO, Feldman G, Smits JAJ, Christian K, et al. (2008). Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy. Depression and Anxiety 25, 167-171. (Pubitemid 351341963)
91. Pande AC, Crockatt JG, Feltner DE, Janney CA, et al. (2003). Pregabalin in generalized anxiety disorder: a placebo-controlled trial. American Journal of Psychiatry 160, 533-540. (Pubitemid 41094262)
92. Pande AC, Crockatt MA, Janne C, Feltner DE (2000). Pregabalin treatment of GAD. Presented at the 153rd Annual Meeting of the American Psychiatric Association, Chicago, IL, 13-18 May (Abstract NR244) (http://www. psych.org/edu/other-res/lib-archives/archives/ meetings/2000nra).
93. Perugi G, Frare F, Toni C, Ruffolo G, et al. (2002). Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid depression or dysthymia: effectiveness, tolerability and predictors of response. Neuropsychobiology 46, 145-149.
94. Pinheiro SN, Laprega MR, Furtado EF (2005). Psychiatric morbidity and alcohol use by pregnant women in a public obstetric service. Revista Saúde Pública 39, 593-598. (Pubitemid 41479563)
95. Pohl RB, Feltner DE, Fieve RR, Pande AC (2005). Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. Journal of Clinical Psychopharmacology 25, 151-158. (Pubitemid 40395093)
96. Pollack MH, Kornstein SG, Spann ME, Crits-Christoph P, et al. (2008). Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. Journal of Psychiatric Research 42, 1176-1184.
97. Pollack MH, Meoni P, Otto MW, Simon N, et al. (2003). Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. Journal of Clinical Psychopharmacology 23, 250-259. (Pubitemid 36807792)
98. Pollack MH, Simon NM, Zalta AK, Worthington J, et al. (2006). Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biological Psychiatry 59, 211-215. (Pubitemid 43208966)
99. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, et al. (2001). Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 62, 350-357. (Pubitemid 32545557)
100. Rickels K, Downing R, Schweizer E, Hassman H (1993). Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Archives of General Psychiatry 50, 884-895. (Pubitemid 23330980)
101. Rickels K, Pollack MH, Feltner DE, Lydiard RB, et al. (2005). Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Archives of General Psychiatry 62, 1022-1030. (Pubitemid 41248382)
102. Rickels K, Pollack MH, Sheehan DV, Haskins JT (2000). Efficacy of extended-release venlafaxine in non-depressed outpatients with generalized anxiety disorder. American Journal of Psychiatry 157, 968-974. (Pubitemid 30412349)
103. Rickels K, Rynn M, Iyengar M, Duff D (2006). Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. Journal of Clinical Psychiatry 67, 41-47. (Pubitemid 43213281)
104. Rickels K, Schweizer E, Csanalosi I, Case WG, et al. (1988). Long-term treatment of anxiety and risk of withdrawal: prospective study of clorazepate and buspirone. Archives of General Psychiatry 45, 444-450.
105. Rickels K, Zaninelli R, McCafferty J, Bellew K, et al. (2003). Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry 160, 749-756. (Pubitemid 41079609)
106. Rodriguez BF, Weisberg RB, Pagano ME, Bruce SE, et al. (2006). Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. Journal of Nervous and Mental Disease 194, 91-97. (Pubitemid 43260187)
107. Rondó PHC, Ferreira RF, Nogueira F, Ribeiro MCN, et al. (2003). Maternal psychological stress and distress as predictors of low birth weight, prematurity and intrauterine growth retardation. European Journal of Clinical Nutrition 57, 266-272. (Pubitemid 36240478)
108. Royal College of Psychiatrists (1997). Benzodiazepines : risks, benefits or dependence. A re-evaluation. Council Report CR59.
109. Rynn M, Khalid-Khan S, Garcia-Espana F (2006). Early response and 8-week treatment outcome in GAD. Depression and Anxiety 23, 461-465. (Pubitemid 44917664)
110. Rynn MA, Russell J, Erickson J, Detke MJ, et al. (2008). Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive titration, placebo-controlled trial. Depression and Anxiety 25, 182-189. (Pubitemid 351499896)
111. Rynn MA, Siqueland L, Rickels K (2001). Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. American Journal of Psychiatry 158, 2008-2014. (Pubitemid 33104106)
112. Simon NM, Connor KM, LeBeau RT, Hoge EA, et al. (2008). Quetiapine augmentation of paroxetine CR for the treatment of generalized anxiety disorder: preliminary findings. Psychopharmacology (Berlin) 197, 675-681.
113. Simon NM, Zalta AK, Worthington III JJ, Hoge EA, et al. (2006). Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depression and Anxiety 23, 373-376. (Pubitemid 44619789)
114. Smoller JW, Block SR, Young MM (2009). Genetics of anxiety disorders: the complex road from DSM to DNA. Depression and Anxiety 26, 965-975.
115. Stein DJ, Ahokas AA, de Bodinat C (2008a). Agomelatine in generalized anxiety disorder: a randomized, placebo-controlled study. Journal of Clinical Psychopharmacology 28, 561-566.
116. Stein DJ, Andersen HF, Goodman WK (2005). Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Annals of Clinical Psychiatry 17, 71-75. (Pubitemid 40967129)
117. Stein DJ, Baldwin DS, Baldinetti F, Mandel F (2008a). Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. European Neuropsychopharmacology 18, 422-430.
118. Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, et al. (2006). Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. Journal of Clinical Psychiatry 67, 1741-1746. (Pubitemid 44955155)
119. Stocchi F, Nordera G, Jokinen RH, Lepola UM, et al. (2003). Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. Journal of Clinical Psychiatry 64, 250-258. (Pubitemid 36457322)
120. Tyrer P, Baldwin DS (2006). Generalised anxiety disorder. Lancet 368, 2156-2166. (Pubitemid 44894560)
121. Tyrer P, Owen R, Dawling S (1983). Gradual withdrawal of diazepam after long-term therapy. Lancet 321, 1402-1406. (Pubitemid 13053303)
122. Tyrer P, Seivewright H, Johnson T (2004). The Nottingham Study of Neurotic Disorder: predictors of 12 year outcome of dysthymic, panic and generalised anxiety disorder. Psychological Medicine 34, 385-394.
123. Weaver J, Miceli J, Shiovitz T, Ramey T, et al. (2009). Adjunctive pregabalin after partial response to SSRI or SNRI in GAD: results of a double-blind, placebo-controlled trial. European Neuropsychopharmacology 19 (Suppl. 3), S593-S594.
124. Weiller E, Bisserbe JC, Maier W, Lecrubier Y (1998). Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO Study on Psychological Problems in General Health Care. British Journal of Psychiatry 173 (Suppl. 34), 18-23. (Pubitemid 28312193)
125. Weissman MM, Pilowsky DJ, Wickramaratne PJ, Talati A, et al. (2006). Remissions in maternal depression and child psychopathology. A STAR*D-Child report. Journal of the American Medical Association 295, 1389-1398.
126. Whalen PJ, Johnstone T, Somerville LH, Nitschke JB, et al. (2008). A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder. Biological Psychiatry 63, 858-863. (Pubitemid 351458450)
127. Wittchen H-U, Carter RM, Pfisster H, Montgomery SA, et al. (2000). Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. International Clinical Psychopharmacology 15, 319-328.
128. Wittchen H-U, Kessler RC, Beesdo K, Krause P, et al. (2002). Generalized anxiety disorder and depression in primary care: prevalence, recognition, and management. Journal of Clinical Psychiatry 63 (Suppl. 8), 24-34. (Pubitemid 34535254)
129. Wittchen H-U, Jacobi F (2005). Size and burden of mental disorders in Europe: a critical review and appraisal of 27 studies. European Neuropsychopharmacology 15, 357-376. (Pubitemid 40943541)